title: Antinociceptive profiles and mechanisms of orally administered vanillin in the mice.
abstract: In the present study, the antinociceptive profiles of vanillin were examined in ICR mice. Vanillin administered orally (from 1 to 10 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured in the acetic acid-induced writhing test. Duration of antinociceptive action of vanillin maintained at least for 30 min. But, the cumulative response time of nociceptive behaviors induced by a subcutaneous (s.c.) formalin injection, intrathecal (i.t.) substance P (0.7 microg) or glutamate (20 microg) injection was not affected by vanillin. Intraperitoneal (i.p.) pretreatment with yohimbine (alpha2-adrenergic receptor antagonist) or naloxone (opioid receptor antagonist) attenuated antinociceptive effect induced by vanillin in the writhing test. However, phentolamine (alpha1-adrenergic receptor antagonist) or methysergide (5-HT serotonergic receptor antagonist) did not affect antinociception induced by vanillin in the writhing test. Our results suggest that vanillin exerts a selective antinociceptive property in the acetic acid-induced visceral inflammatory pain model. Furthermore, this antinociceptive effect of vanillin may be mediated by alpha2-adrenergic and opioid receptors, but not alpha1-adrenergic and serotonergic receptors.
authors.affiliation: Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon 200-702, Korea.
authors.forename: Soo-Hyun
authors.initials: SH
authors.lastname: Park
authors.forename: Yun-Beom
authors.initials: YB
authors.lastname: Sim
authors.forename: Seung-Min
authors.initials: SM
authors.lastname: Choi
authors.forename: Young-Jun
authors.initials: YJ
authors.lastname: Seo
authors.forename: Min-Soo
authors.initials: MS
authors.lastname: Kwon
authors.forename: Jin-Koo
authors.initials: JK
authors.lastname: Lee
authors.forename: Hong-Won
authors.initials: HW
authors.lastname: Suh
mesh_terms: D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001547:Benzaldehydes / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism
chemical_list: D000700:Analgesics; D001547:Benzaldehydes; D018341:Receptors, Adrenergic, alpha-2; D011957:Receptors, Opioid; C100058:vanillin